Funding round brings in $33M for cholesterol drug developer

04/26/2013 | Xconomy

Esperion Therapeutics said it secured $33 million in a preferred stock funding round led by Longitude Capital and it will use the money to fund clinical trials. The Ann Arbor, Mich.-based firm is developing a cholesterol-lowering drug for patients who can't take statins. The drug, called ETC-1002, is in midstage development.

View Full Article in:

Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL